Nicox S.A.
Ophthalmology company developing therapies based on a nitric oxide-donating platform.
COX | PA
Overview
Corporate Details
- ISIN(s):
- FR0013018124 (+6 more)
- LEI:
- 969500EZGEO9W4JXR353
- Country:
- France
- Address:
- SOPHIA, 06410 BIOT
- Website:
- https://www.nicox.com/
Description
Nicox S.A. is an international ophthalmology company focused on the research and development of innovative therapeutic solutions to maintain vision and improve ocular health. The company's lead product candidate is NCX 470, a novel nitric oxide (NO)-donating bimatoprost analog in late-stage clinical development for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox's pipeline is based on its proprietary NO-donating research platform. The company has also developed two approved ophthalmic products: VYZULTA® (latanoprostene bunod ophthalmic solution), licensed exclusively to Bausch + Lomb, and ZERVIATE® (cetirizine ophthalmic solution), licensed to various partners for commercialization.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2022-07-05 07:30 |
Nicox: Half-year liquidity contract statement for NICOX
|
English | 338.4 KB | ||
| 2022-07-01 17:45 |
Nombre de droits de vote au 30 juin 2022
|
French | 189.6 KB | ||
| 2022-07-01 17:45 |
Number of voting rights as of June 30, 2022
|
English | 190.2 KB | ||
| 2022-06-22 18:00 |
Assemblée Générale Extraordinaire de Nicox du 11 juillet 2022
|
French | 5.9 MB | ||
| 2022-06-22 18:00 |
Nicox Extraordinary General Meeting of July 11, 2022
|
English | 6.2 MB | ||
| 2022-06-14 07:30 |
Nicox : Assemblée Générale Ordinaire 2022
|
French | 322.6 KB | ||
| 2022-06-14 07:30 |
Nicox: 2022 Ordinary Shareholder Meeting
|
English | 249.4 KB | ||
| 2022-06-03 10:00 |
Number of voting rights as of June 3, 2022
|
French | 189.6 KB | ||
| 2022-06-03 10:00 |
Number of voting rights as of June 3, 2022
|
English | 190.1 KB | ||
| 2022-06-03 08:30 |
Nicox: 2022 Extraordinary Shareholder Meeting
|
English | 249.2 KB | ||
| 2022-06-03 08:30 |
Nicox : Assemblée Générale Extraordinaire 2022
|
French | 321.8 KB | ||
| 2022-06-03 07:30 |
Nicox : Résultats de l’étude de phase 3 Mont Blanc pour le NCX 470 dans le glau…
|
French | 440.9 KB | ||
| 2022-06-03 07:30 |
Nicox Accelerates Topline Results from NCX 470 Mont Blanc Phase 3 Glaucoma Tria…
|
English | 352.9 KB | ||
| 2022-06-01 17:45 |
Number of voting rights as of May 31, 2022
|
English | 190.1 KB | ||
| 2022-06-01 17:45 |
Nombre de droits de vote au 31 mai 2022
|
French | 189.6 KB |
Automate Your Workflow. Get a real-time feed of all Nicox S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Nicox S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Nicox S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
